Aurélie Maran-Gonzalez

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

William Jacot, Aurélie Maran-Gonzalez, Océane Massol et al. · Cancers · 2021 · 111 citations · Full text

Medicine, Oncology, Pathology +16

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Thomas Grinda, Natacha Joyon, Amélie Lusque et al. · npj Breast Cancer · 2021 · 90 citations · Full text

Medicine, Oncology, Breast Oncology +14

PHOX2B Immunolabeling

Franck Bielle, Paul Fréneaux, Corinne Jeanne‐Pasquier et al. · The American Journal of Surgical Pathology · 2012 · 61 citations

Medicine, Oncology, Pediatrics +16

Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma

Madi Y. Cissé, Samuel Pyrdziak, Nelly Firmin et al. · Science Translational Medicine · 2020 · 47 citations · Full text

Medicine, Cancer Biology, Oncology +17

<scp>HER</scp>2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a <scp>F</scp>rench regional cohort

Philippe Rouanet, Pascal Roger, Emilie Rousseau et al. · Cancer Medicine · 2014 · 45 citations · Full text

Medicine, Oncology, Metastasis +13